IRIS
BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.016
EU - Europa 3.393
AS - Asia 2.506
SA - Sud America 709
Continente sconosciuto - Info sul continente non disponibili 171
AF - Africa 97
Totale 10.892
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.850
RU - Federazione Russa 1.061
IE - Irlanda 945
SG - Singapore 786
CN - Cina 531
BR - Brasile 529
VN - Vietnam 435
HK - Hong Kong 418
SE - Svezia 310
IT - Italia 308
UA - Ucraina 222
FR - Francia 160
DE - Germania 157
CA - Canada 80
GB - Regno Unito 80
AR - Argentina 75
BD - Bangladesh 64
ID - Indonesia 63
IN - India 41
KR - Corea 32
MX - Messico 32
EC - Ecuador 28
ZA - Sudafrica 28
VE - Venezuela 25
CO - Colombia 23
FI - Finlandia 23
BE - Belgio 20
IQ - Iraq 20
BJ - Benin 19
JP - Giappone 19
PY - Paraguay 17
EU - Europa 15
NL - Olanda 15
AT - Austria 13
ES - Italia 12
MA - Marocco 12
JM - Giamaica 11
PL - Polonia 11
CR - Costa Rica 10
TR - Turchia 10
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
NP - Nepal 8
RO - Romania 8
CL - Cile 7
DZ - Algeria 7
EE - Estonia 7
KE - Kenya 7
PH - Filippine 7
TT - Trinidad e Tobago 7
UZ - Uzbekistan 7
EG - Egitto 6
IL - Israele 6
IR - Iran 6
TN - Tunisia 6
BG - Bulgaria 5
LT - Lituania 5
PK - Pakistan 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
ET - Etiopia 4
HN - Honduras 4
HU - Ungheria 4
JO - Giordania 4
KZ - Kazakistan 4
RS - Serbia 4
BB - Barbados 3
BS - Bahamas 3
CH - Svizzera 3
CW - ???statistics.table.value.countryCode.CW??? 3
GT - Guatemala 3
KG - Kirghizistan 3
LB - Libano 3
QA - Qatar 3
AL - Albania 2
BO - Bolivia 2
DK - Danimarca 2
GD - Grenada 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
PE - Perù 2
PR - Porto Rico 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
LV - Lettonia 1
MF - Saint Martin 1
MK - Macedonia 1
Totale 10.729
Salva come PNG Salva come JPEG
Città #
Dublin 929
Hong Kong 415
San Jose 390
Jacksonville 377
Singapore 314
Council Bluffs 310
Ashburn 203
Beijing 169
Ho Chi Minh City 143
Phoenix 140
Moscow 130
Lauterbourg 122
Wilmington 121
Princeton 120
Lawrence 118
Columbus 116
Chandler 109
San Mateo 106
Los Angeles 97
Hanoi 89
Santa Clara 67
Munich 56
São Paulo 55
Buffalo 49
Dallas 38
New York 37
Redondo Beach 31
Seoul 31
Dong Ket 30
Jakarta 30
North Bergen 28
Orem 26
Piemonte 26
Ann Arbor 25
Boardman 23
Brooklyn 20
Milan 20
Montreal 20
Atlanta 19
Brussels 19
Cotonou 19
Houston 19
Tianjin 19
Novara 17
Frankfurt am Main 16
Nuremberg 16
Tokyo 16
Da Nang 15
Shanghai 15
Toronto 15
Turin 15
Chicago 14
Haiphong 14
Norwalk 14
Rio de Janeiro 14
Brasília 13
Denver 13
Dhaka 13
Guangzhou 13
Helsinki 13
Johannesburg 13
Mexico City 13
Rome 13
London 12
Philadelphia 12
Falkenstein 11
Guayaquil 11
Naples 11
San Francisco 11
Amsterdam 10
Porto Alegre 10
San José 10
Thái Bình 10
Warsaw 10
Belo Horizonte 9
Caracas 9
Chennai 9
Hangzhou 9
Quito 9
Turku 9
Andover 8
Biên Hòa 8
Boston 8
Fairfield 8
Hải Dương 8
Kingston 8
Seattle 8
Brno 7
Cape Town 7
Casablanca 7
Charlotte 7
Manchester 7
San Diego 7
Sylmar 7
Tashkent 7
West Jordan 7
Alessandria 6
Baghdad 6
Curitiba 6
Detroit 6
Totale 5.825
Salva come PNG Salva come JPEG
Nome #
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 275
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 214
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 205
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 123
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 119
Coinfection with other respiratory pathogens in COVID-19 patients 114
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir 112
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 112
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 110
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 108
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients 108
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 106
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 106
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 105
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 105
Ceftobiprole perspective: Current and potential future indications 105
Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study 104
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 104
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 102
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir 102
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 101
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 101
Prevalenza e fattori di rischio dell'insorgenza di psicosi acuta 59 nei pazienti anziani ospedalizzati per infezione da Sars-COV-2: studio retrospettivo 100
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon] 98
A rare SARS-CoV-2 complication: Candida spondylodiscitis following SARS-CoV-2 infection—two case reports 96
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 96
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 96
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 96
Lo studio filologico applicato alla descrizione della “pestilenza” di Atene di Tucidide: dall’analisi del testo agli aspetti di epidemiologia e malattie infettive 95
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 94
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 94
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 92
Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? 92
Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir 91
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy 91
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 90
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 90
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 90
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 90
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 89
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 89
Long-COVID syndrome in hospitalized patients after 2 years of follow-up 88
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 88
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 88
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 87
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 87
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? 87
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 86
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E 84
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 83
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 83
Real-World Outcomes of Neutralizing Monoclonal Antibody Treatment in Patients Affected by Nosocomial Coronavirus Disease 2019 82
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 82
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 82
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 82
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 82
Behavioural health issues in post coronavirus disease (COVID) syndrome and suicide risk: a narrative review 81
Combination therapy in chronic hepatitis B: what are the real benefits? 81
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 81
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 81
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 80
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 80
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis 79
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon 79
Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group 79
Clinical characteristics and outcomes in hospitalized patients with West Nile neuroinvasive disease: A case-series analysis 78
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 78
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 78
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 78
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes 77
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 77
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study 77
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 76
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 76
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 76
Predictors of Mortality in Patients with COVID-19 Infection in Different Health- Care Settings: A Retrospective Analysis from a CORACLE Study Group 75
Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry 75
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 75
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes 74
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 74
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 74
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis 74
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 73
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools 73
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 73
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 73
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 72
Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers 72
Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study 72
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 71
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 71
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 71
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms 71
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 71
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 69
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 69
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 69
Letter: liver involvement and mortality in COVID-19—the role of anti-viral therapy should be considered 69
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 68
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 68
Totale 9.069
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.781
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.781
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022529 0 0 0 47 20 21 27 16 93 24 120 161
2022/20231.564 135 111 89 24 36 89 33 61 913 13 44 16
2023/2024441 26 19 18 9 64 6 116 15 13 10 7 138
2024/20251.438 14 11 100 25 14 67 186 157 432 201 40 191
2025/20264.513 176 206 445 828 278 304 617 670 278 314 168 229
2026/20271.498 242 390 424 442 0 0 0 0 0 0 0 0
Totale 10.892